Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

Autor:	Martin, M, Zielinski, C, Ruiz-Borrego, M, Carrasco, E, Ciruelos, E, Munoz, M, Bermejo, B, Margeli, M, Turner, N, Casas, M, Anton, A, Csoszi, T, Corsaro, M, Murillo, L, Morales, S, Alba, E, Bartlett, CH, Koehler, M, Guerrero, A, Kahan, Z, Gil-Gil, M
Rok vydání:	2020
Zdroj:	Cancer Research r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname
ISSN:	0008-5472
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::6fe1f6e6553e13d596085a8e2b16ac7d https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4318 Zobrazit plný text záznamu